bupropion and Recrudescence

bupropion has been researched along with Recrudescence in 95 studies

Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.

Research

Studies (95)

Authors

Clinical Trials (16)

Trial Overview

Trial Outcomes

Functioning, as Measured by the Social Adjustment Scale (SAS) Summary Score

Social adjustment was measured using the Social Adjustment Scale (SAS). The SAS is a self-report scale that assesses depressive symptoms and functioning in nine social and work-related domains generating a total score that is indicative of a subject's overall level of social adjustment. Subjects rate their own social functioning over times on a 5-point scale on items covering work for pay, housework, extended family, parenting, marital status, social activity and leisure, family unit and student status (sub-scales). Mean values of all the sub-scales are used, with a range from 0-5. Higher score = worse outcome … worse functioning (NCT00519428)
Timeframe: 12 weeks

Quality of Life, as Measured by the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Short Form (SF)

"The Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) intends to measure quality of life in 16 domains. A summary score is computed by adding the scores and dividing by 16 (or the number of answered items if some are not answered).~The minimum raw score on the Q-LES-Q-SF is 14, and the maximum score is 70. Higher score means more satisfaction." (NCT00519428)
Timeframe: 12 weeks

Remission: Persistent Hamilton Rating Scale for Depression, 17 Items (HAM-D 17) <= 7, With no HAM-D 17 >7 Through Week 12

Chi square comparison of rates of persistent remission (i.e., no subsequent Hamilton Rating Scale for Depression, 17 items [HAMD-D 17] > 7 once HAMD-D 17 <= 7); Dual rate vs. Escitalopram only rate and Dual rate vs. Bupropion only rate. (NCT00519428)
Timeframe: 12 weeks

Severity of Depressive Symptoms as Measured by Hamilton Rating Scale for Depression (HAM-D 17)

"Last summary score rating on the 17-item Hamilton Rating Scale for Depression Eight items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Nine are scored from 0-2. Range 0-58.~0-7 = Normal 8-13 = Mild Depression 14-18 = Moderate Depression 19-22 = Severe Depression~≥ 23 = Very Severe Depression" (NCT00519428)
Timeframe: 12 weeks

Time to Remission, Defined by the Week of Onset of Persistent Hamilton Rating Scale for Depression (HAM-D 17) <= 7, With no Subsequent HAM-D 17 > 7

Life Table Survival Analysis run twice, once comparing Dual Therapy (i.e., Bupropion + Escitalopram) to Bupropion alone (i.e., Bupropion + Placebo) and once comparing Dual Therapy to Escitalopram alone (i.e., Escitalopram + Placebo). Because both analyses must significantly favor Dual Therapy, each individual analysis must reach a critical alpha = .0916 in order to reach an over-all alpha = .05. (NCT00519428)
Timeframe: 12 weeks

Quality of Life Inventory

The Quality of Life Inventory (QOLI) is a 32-item comprehensive self-report of satisfaction in 16 areas of life, such as love, work, and health. Each area is rated in terms of satisfaction and the relationship of that area to overall quality of life. It yields an overall raw score and satisfaction ratings for the 16 individual areas of life. The QOLI raw score is an average of weighted satisfaction ratings computed only over areas of life judged to be Important or Extremely Important to the respondent. Higher scores indicate higher reported quality of life. (NCT00590863)
Timeframe: Measured at Month 7

Quick Inventory of Depressive Symptoms

Percentage of patients that achieve remission, as defined as QIDS total score below 6 for last 2 study visits. QIDS depression scores range from 0 (normal) to 27 (very severe). (NCT00590863)
Timeframe: Measured at Month 7

Latency to Relapse

Latency to Relapse during the first 12 months post-quit, with relapse defined as 7 consecutive days of smoking; this outcome will be analyzed in a Cox regression survival analysis model with non-relapsers coded as right-censored (NCT01120704)
Timeframe: Assessed during the first 12 months post-quit after target quit day

Self-Reported 7-Day Point-Prevalence Abstinence

"Self-Reported 7-Day Point-Prevalence Abstinence is a dichotomous outcome with values of 0 and 1 where 0=smoking on one or more of the past 7 days at the assessment endpoint (52 weeks post-quit) and 1=no smoking on any of the past 7 days at the assessment endpoint (i.e., abstinent for the past 7 days); this outcome will be analyzed in a logistic regression analysis model.~Note: This abstinence primary outcome replaces latency to relapse (now designated as a secondary outcome) because reviewers of the now-accepted manuscript (at the journal Addiction) advised us to change the primary outcome to the current week 52 Self-Reported 7-Day Point-Prevalence Abstinence." (NCT01120704)
Timeframe: Assessed at 52 weeks after target quit day

Number of Participants With Salivary Cotinine-verified Smoking Abstinence at 6 Months

Salivary cotinine-verified smoking abstinence at 6 months. A cut point of 15 ng/ml was used to differentiate smokers from nonsmokers. (NCT00666978)
Timeframe: 6 months

Number of Participants for Each CYP2B6 Allele

We genotyped CYP2B6 in 268 from the Bupropion arm as this polymorphism is related to bupropion metabolism. (NCT00666978)
Timeframe: Week 3

Number of Slow and Fast Metabolizers by Genotype

"Analyzed CYP2A6 by genotype. The variants present in people in the slow genotype group include *17, *20, *23,*27, *35, *9, *2, *25, *26, and *4. The fast metabolizers have none of the variant alleles tested.~Slow metabolizers have any reduction or loss of function variant. Fast metabolizers are *1/*1 genotype by exclusion." (NCT00666978)
Timeframe: Week 0

Number of Slow and Fast Metabolizers by Metabolite Ratio

"Analyzed CYP2A6 by activity, called the nicotine metabolite ratio using a split between slow and fast metabolism at 0.31.~The variants present in people in the slow genotype group include *17, *20, *23,*27, *35, *9, *2, *25, *26, and *4. The fast metabolizers have none of the variant alleles tested.~Blood samples were collected for 3HC/COT ratio at Week 0." (NCT00666978)
Timeframe: Weeks 0

Continuous Abstinence at End of Treatment (Self-report)(Defined as the Number of Consecutive Days Without Smoking a Cigarette for Each Subject)

A self-report measure of continuous abstinence at end of treatment. It is defined as the number of consecutive days without smoking a cigarette for each subject, as determined by the Timeline Followback (TLFB), completed by research staff. The TLFB is an assessment tool that obtains estimates of daily smoking. Using a calendar, people provide retrospective estimates of their daily smoking over a specified time period that can vary up to 12 months from the interview date. The TLFB has also been used to assess other forms of substance abuse (e.g., alcohol, drugs, etc.). (NCT00326781)
Timeframe: End of Treatment (8-weeks after quit date)

Verified 7-day Point Prevalence Abstinence at End Of Treatment.

"End-of-Treatment (EOT) is defined as the phone survey that takes place at the end of each subject's nicotine replacement therapy treatment. The EOT took place up to 8 weeks after participants began the study and also utilized the Timeline Followback. It is a 7-day point prevalence measure describing a subject's ability to remain abstinent from smoking for the 7 previous days occurring before a subject's EOT phone survey.~This was verified by a Carbon Monoxide breath reading taking place within a week of a subject's End of Treatment phone survey." (NCT00326781)
Timeframe: End of Treatment

Biochemically Validated Abstinence at 6-month Follow-up

measurement of exhaled carbon monoxide using a Smokerlyzer, and a saliva cotinine test (NCT03717051)
Timeframe: 6 months

Number of Participants Who Enroll in Any Smoking Cessation Service in Hong Kong

Number of participants who enroll in any smoking cessation service in Hong Kong (NCT03717051)
Timeframe: 1 month

Number of Participants Who Enroll in Any Smoking Cessation Service in Hong Kong

Number of participants who enroll in any smoking cessation service in Hong Kong (NCT03717051)
Timeframe: 3 months

Number of Participants With Self-reported Quit Attempt

No smoking for at least 24 hours in the past month (NCT03717051)
Timeframe: 1 month

Number of Participants With Self-reported Quit Attempt

No smoking for at least 24 hours in the past month (NCT03717051)
Timeframe: 3 months

Number of Participants With Self-reported Tobacco Abstinence in Past 30 Days

self-reported tobacco abstinence in past 30 days (NCT03717051)
Timeframe: 3 months

Number of Participants With Self-reported Tobacco Abstinence in Past 30 Days

self-reported tobacco abstinence in past 30 days (NCT03717051)
Timeframe: 6 months

Number of Participants With Self-reported Tobacco Abstinence in Past 7 Days

self-reported tobacco abstinence in past 7 days (NCT03717051)
Timeframe: 3 months

Number of Participants With Self-reported Tobacco Abstinence in Past 7 Days

self-reported tobacco abstinence in past 7 days (NCT03717051)
Timeframe: 6 months

Number of Participants With Self-reported Use of NRT in Past Week/Month

self-reported use of NRT in past week/month (NCT03717051)
Timeframe: 1 month

Number of Participants With Self-reported Use of NRT in Past Week/Month

self-reported use of NRT in past week/month (NCT03717051)
Timeframe: 3 months

Progression Towards Smoking Cessation

progression towards smoking cessation as measured by Incremental Behavior Change toward Smoking cessation (IBC-S). The minimum value is 3 and the maximum value is 27. Higher scores mean a better outcome. (NCT03717051)
Timeframe: 1 month

Progression Towards Smoking Cessation

progression towards smoking cessation as measured by Incremental Behavior Change toward Smoking cessation (IBC-S). The minimum value is 3 and the maximum value is 27. Higher scores mean a better outcome. (NCT03717051)
Timeframe: 3 months

Progression Towards Smoking Cessation

progression towards smoking cessation as measured by Incremental Behavior Change toward Smoking cessation (IBC-S). The minimum value is 3 and the maximum value is 27. Higher scores mean a better outcome. (NCT03717051)
Timeframe: 6 months

Perceived Importance, Difficulty and Confidence to Quit Smoking

Self-efficacy will be evaluated according to the importance of quitting on a scale of 0 to 10 (0, least important; 10, most important), difficulty of quitting on a scale of 0 to 10 (0, least difficult; 10, most difficult), and confidence in quitting on a scale of 0 to 10 (0, least confident; 10, most confident) (NCT03717051)
Timeframe: 3 months

Perceived Importance, Difficulty and Confidence to Quit Smoking

Self-efficacy will be evaluated according to the importance of quitting on a scale of 0 to 10 (0, least important; 10, most important), difficulty of quitting on a scale of 0 to 10 (0, least difficult; 10, most difficult), and confidence in quitting on a scale of 0 to 10 (0, least confident; 10, most confident) (NCT03717051)
Timeframe: 6 months

Perceived Importance, Difficulty and Confidence to Quit Smoking

Self-efficacy will be evaluated according to the importance of quitting on a scale of 0 to 10 (0, least important; 10, most important), the difficulty of quitting on a scale of 0 to 10 (0, least difficult; 10, most difficult), and confidence in quitting on a scale of 0 to 10 (0, least confident; 10, most confident). For the scale of measuring quitting importance and confidence, higher scores mean a better outcome and for the scale of measuring difficulty, higher scores mean a worse outcome. (NCT03717051)
Timeframe: 1 month

Symptoms of Depression Using the Center for Epidemiologic Studies Depression Scale (CES-D)

Symptoms of nicotine withdrawal measured using Center for Epidemiologic Studies Depression Scale (CES-D). Center of Epidemiologic Studies Depression Scale (CESD) a 20-item measure that asks caregivers to rate how often over the past week they experienced symptoms associated with depression, such as restless sleep, poor appetite, and feeling lonely. Response options range from 0 to 3 for each item (0 = Rarely or None of the Time, 1 = Some or Little of the Time, 2 = Moderately or Much of the time, 3 = Most or Almost All the Time). Scores range from 0 to 60, with high scores indicating greater depressive symptoms. The average value was estimated from Baseline to 8 months (NCT00507728)
Timeframe: Baseline to 8 months

Abstinence at 6 Months by DRD2 A1 Allele

Values represent change in probability of abstinence for unit change in emotional reactivity. Abstinence data collected using a timeline follow-back (TLFB) procedure. Continuous Abstinence was defined as no smoking within the last 4 weeks of treatment. It is scored as 0 if the participant smoked during the specific interval, and 1 if the participant abstained from smoking. (NCT00507728)
Timeframe: Baseline to 6 Month ( the effects shown are the increase/decrease in probability of abstinence for 1 unit increase in the predictor)

Emotional Reactivity By Pharmacotherapy

Emotional reactivity measured by the peak eye blink electromyography (EMG) of the orbicularis oculi (ORB) muscle responses to acoustic startle probe delivered during the presentation of emotionally valent stimuli (pleasant, unpleasant, neutral, and smoking-related pictures). A single value was estimated by averaging within the specific time interval. (NCT00507728)
Timeframe: Baseline to 1 month

Emotional Reactivity By Pharmacotherapy Moderated by DRD2 A1 Allele

The emotional reactivity (ORB EMG) of smokers during cessation will be moderated by genotype. A single value was estimated by averaging within the specific time interval. During a quit attempt, smokers were evaluated on how they react to smoking related cues. An interaction term was then formed by the reactivity to smoking stimulus and genotype. (NCT00507728)
Timeframe: Baseline to 1 month

Heart Rate Response

Heart Rate Response. A single value was estimated by averaging within the specific time interval. During a quit attempt, smokers were evaluated on how they react to smoking related cues. An interaction term was then formed by the reactivity to smoking stimulus and genotype. (NCT00507728)
Timeframe: Baseline to 1 month

Measures of Smoking Satisfaction and Psychological Reward Using the Modified Cigarette Evaluation Questionnaire (mCEQ) Subscales

Modified Cigarette Evaluation Questionnaire (mCEQ). mCEQ Smoking satisfaction: range (1-21); mCEQ Psychological Reward: range(1-35); mCEQ Aversion: range (1-14); mCEQ Enjoyment of Resp.Tract Sens: range (1-7); mCEQ Craving Reduction: range (1-7). For all scales of mCEQ higher scores indicate worse outcomes (greater intensity of smoking effect). Scores of mCEQ Smoking satisfaction, mCEQ psychological reward and mCEQ aversion were summed to create the subscales. mCEQ Enjoyment of Resp Tract Sens and mCEQ Craving Reduction were single items. (NCT00507728)
Timeframe: Baseline to 8 months

Skin Conductance Response

Skin conductance response (SCR) amplitude measured by placing an electrodermal response transducer on the fore and ring fingers of the participants non-dominant hand, and heart rate (HR) was collected by placing a photoelectric pulse plethysmogram transducer on the middle finger of the participants non-dominant hand, during the presentation of emotionally valent stimuli (positive, negative, neutral, and smoking-related pictures). A single value was estimated by averaging within the specific time interval. (NCT00507728)
Timeframe: Baseline to 1 month

Smoking Abstinence at 3 Months

Values represent change in probability of abstinence for unit change in emotional reactivity. Abstinence data collected using a timeline follow-back (TLFB) procedure. Continuous Abstinence was defined as no smoking within the last 4 weeks of treatment. It is scored as 0 if the participant smoked during the specific interval, and 1 if the participant abstained from smoking. (NCT00507728)
Timeframe: Baseline to 3 months

Smoking Abstinence at 3 Months by DRD2 A1 Allele

Values represent change in probability of abstinence for unit change in emotional reactivity. Abstinence data collected using a timeline follow-back (TLFB) procedure. Continuous Abstinence was defined as no smoking within the last 4 weeks of treatment. It is scored as 0 if the participant smoked during the specific interval, and 1 if the participant abstained from smoking. (NCT00507728)
Timeframe: Baseline to 3 Month

Smoking Abstinence at 6 Months

Values represent change in probability of abstinence for unit change in emotional reactivity. Abstinence data collected using a timeline follow-back (TLFB) procedure. Continuous Abstinence was defined as no smoking within the last 4 weeks of treatment. It is scored as 0 if the participant smoked during the specific interval, and 1 if the participant abstained from smoking. (NCT00507728)
Timeframe: Abstinence at 6 Months ( the effects shown are the increase/decrease in probability of abstinence for 1 unit increase in the predictor)

Symptoms of Nicotine Withdrawal and Negative Affect Using Positive and Negative Affect Scale (PANAS)

Symptoms of nicotine withdrawal and negative affect were measured using the Positive and Negative Affect Scale (PANAS). The Positive and Negative Affect Schedule (PANAS) is a self-report questionnaire to measure both positive and negative affect. Each item is rated on a 5-point scale of 1 (not at all) to 5 (very much). Scores can range from 10-50 for both the Positive and Negative Affect with the lower scores representing lower levels of Positive/Negative Affect and higher scores representing higher levels of Positive/Negative Affect. The average value was estimated from Baseline to 8 months (NCT00507728)
Timeframe: Baseline to 8 months

Symptoms of Nicotine Withdrawal Using the Wisconsin Smoking Withdrawal Scale (WSWS)

Symptoms of nicotine withdrawal measured using Wisconsin Smoking Withdrawal Scale (WSWS). The Wisconsin Withdrawal Scale (WSWS) contains 7 factors: Anger, Anxiety, Sadness, Concentration, Craving, Sleep, and Hunger. WSWS consists of 28 items that are scored on a 5-point Likert type scale (0 = strongly disagree, 4 = strongly agree). A single value was estimated by averaging within the specific time interval. Higher values represent worse outcome. The average value was estimated from Baseline to 8 months (NCT00507728)
Timeframe: Baseline to 8 months

7-day Point Prevalence of Smoking Abstinence

"Number of participants who report Not Smoking (not even a puff) in past 7 days when asked at week 8" (NCT01015170)
Timeframe: End of Treatment (8 weeks after Zyban start date)

Reviews

17 reviews available for bupropion and Recrudescence

Trials

37 trials available for bupropion and Recrudescence

Other Studies

41 other studies available for bupropion and Recrudescence